VistaGen Therapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Vistagen Therapeutics Inc Announces $36 Million Strategic Financing Agreement With Bergamo Acquisition Corp's Subsidiary
Vistagen Therapeutics Inc announced the signing of a strategic financing agreement with the European subsidiary of Bergamo Acquisition Corp., a global diversified investment holding company. Under the terms of the agreement, Bergamo's European subsidiary will invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen Common Stock at a price of $0.50 per share. The Company's self-placed strategic financing does not include warrants or any investment banking fees. The transaction is scheduled to close on or before April 30, 2013. At closing, the shares issued in connection with the strategic financing will represent a majority of the issued and outstanding shares of VistaGen's Common Stock. VistaGen plans to use proceeds of the financing to accelerate and expand stem cell technology-based drug rescue programs.
Latest Key Developments in Pharmaceuticals
- Merck & Co Inc announces FDA approves RAGWITEK Sublingual tablet as immunotherapy to treat short ragweed Pollen-Induced Allergic Rhinitis with or without conjunctivitis in adults
- GlaxoSmithKline Plc and Genmab A/S receive FDA approval for Arzerra(r) (ofatumumab) as first-line treatment in combination with Chlorambucil for Patients with Chronic Lymphocytic Leukemia
- OPKO acquires dry powder inhaler to treat respiratory disorders
- American Capital receives $210 mln from sale of SPL Acquisition Corp to Shenzhen Hepalink Pharmaceutical Co., Ltd
- Share this
- Digg this